RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …

Simple Summary Recently, radiogenomics has played a significant role and offered a new
understanding of cancer's biology and behavior in response to standard therapy. It also …

Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRAS G12C-
mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary
disease with a median survival of 2–4 years after diagnosis. A significant number of IPF …

KRAS mutations are the most common genetic abnormalities in cancer, but the distribution
of specific mutations across cancers and the differential responses of patients with specific …

Introduction Although KRAS mutations in NSCLC have been considered mutually exclusive
driver mutations for a long time, there is now growing evidence that KRAS-mutated NSCLC …

Lung diseases carry a significant burden of morbidity and mortality worldwide. The advent of
digital pathology (DP) and an increase in computational power have led to the development …

Objectives Non-small cell lung cancer (NSCLC) is a heterogeneous disease with unique
combinations of somatic molecular alterations in individual patients, as well as significant …

Simple Summary KRAS is the most frequently mutated oncogene in non-small cell lung
cancers (NSCLC), with a frequency around 30%, and among them KRAS G12C mutation …